Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Authors

Michael E. Nassif
Sheryl Windsor
Fengming Tang
Yevgeniy Khariton
Mansoor Husain
Silvio E. Inzucchi
Darren McGuire
Bertram Pitt
Benjamin M. Scirica
Bethany Austin
Mark Drazner
Michael Fong
Michael M. Givertz
Robert Gordon
Rita Jermyn
Stuart Katz
Sumant Lamba
David E. Lanfear, Henry Ford HealthFollow
Shane LaRue
JoAnn Lindenfeld
Michael Malone
Kenneth B. Margulies
Robert Mentz
R K. Mutharasan
Michael Pursley
Guillermo Umpierrez
Mikhail Kosiborod

Recommended Citation

Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire D, Pitt B, Scirica BM, Austin B, Drazner M, Fong M, Givertz MM, Gordon R, Jermyn R, Katz S, Lamba S, Lanfear D, LaRue S, Lindenfeld J, Malone M, Margulies KB, Mentz R, Mutharasan RK, Pursley M, Umpierrez G, and Kosiborod M. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation 2019.

Document Type

Article

Publication Date

9-16-2019

Publication Title

Circulation

PubMed ID

31524498

ePublication

ePub ahead of print